myotubularin related protein 9 like, pseudogeneGenealiases: []
Q-omics provides the consensus-scored MTMR9LP profile across patient tissues and cancer cell-line models. MTMR9LP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MTMR9LP is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, MTMR9LP RNA expression shows 18,732 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where MTMR9LP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTMR9LP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTMR9LP survival associations across molecular data types. MTMR9LP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTMR9LP RNA expression–survival associations across cancer types. High MTMR9LP expression shows unfavorable associations in MESO and KIRC, but favorable associations in HNSC, PAAD, LUAD and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for MTMR9LP RNA expression.
This table summarizes MTMR9LP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MTMR9LP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTMR9LP shows lower tumor expression in KICH, LUSC, BRCA and KIRP and higher tumor expression in COAD and LIHC. The KICH box plot shows higher MTMR9LP RNA expression in normal versus tumor tissue (log2 FC = −1.241, t-test p < 0.001).
This table shows molecular features associated with MTMR9LP in patient tissues and cancer cell lines. In patient samples, MTMR9LP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MTMR9LP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS.
